[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 112,425,456
  • Shares Outstanding, K 253,805
  • Annual Sales, $ 12,001 M
  • Annual Income, $ 3,953 M
  • EBIT $ 4,681 M
  • EBITDA $ 4,891 M
  • 60-Month Beta 0.30
  • Price/Sales 9.45
  • Price/Cash Flow 25.42
  • Price/Book 5.87

Options Overview Details

View History
  • Implied Volatility 28.59% (-0.07%)
  • Historical Volatility 23.43%
  • IV Percentile 42%
  • IV Rank 26.97%
  • IV High 46.24% on 02/12/26
  • IV Low 22.08% on 08/27/25
  • Expected Move (DTE 3) 4.25 (0.95%)
  • Put/Call Vol Ratio 3.88
  • Today's Volume 1,660
  • Volume Avg (30-Day) 2,111
  • Put/Call OI Ratio 0.79
  • Today's Open Interest 51,209
  • Open Int (30-Day) 50,182
  • Expected Range 441.52 to 450.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 34 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $4.25
  • Number of Estimates 6
  • High Estimate $4.47
  • Low Estimate $3.98
  • Prior Year $4.00
  • Growth Rate Est. (year over year) +6.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
420.01 +6.13%
on 06/03/26
456.68 -2.39%
on 05/14/26
+15.95 (+3.71%)
since 05/08/26
3-Month
412.27 +8.13%
on 05/05/26
507.92 -12.24%
on 03/10/26
-15.10 (-3.28%)
since 03/09/26
52-Week
362.50 +22.97%
on 08/11/25
507.92 -12.24%
on 03/10/26
-0.38 (-0.09%)
since 06/09/25

Most Recent Stories

More News
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of

VRTX : 445.77 (+0.63%)
Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the Goldman Sachs 47th Annual Global Healthcare Conference. Dr. Reshma Kewalramani, President and...

VRTX : 445.77 (+0.63%)
Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?

Despite Vertex Pharmaceuticals' underperformance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

XLV : 154.57 (+1.26%)
VRTX : 445.77 (+0.63%)
REGN : 616.18 (+0.79%)
AMGN : 344.57 (-0.34%)
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

- FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026 –

VRTX : 445.77 (+0.63%)
Is Regeneron Pharmaceuticals Stock Underperforming the Dow?

Regeneron Pharmaceuticals has underperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.

VRTX : 445.77 (+0.63%)
$DOWI : 50,872.11 (+0.17%)
REGN : 616.18 (+0.79%)
2 Healthcare Stocks with Exciting Potential and 1 Facing Challenges

2 Healthcare Stocks with Exciting Potential and 1 Facing Challenges

COO : 68.62 (+2.74%)
VRTX : 445.77 (+0.63%)
CLOV : 4.29 (+9.44%)
What Are Wall Street Analysts' Target Price for Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals has underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.

$SPX : 7,386.65 (-0.26%)
JPM : 312.70 (+0.51%)
VRTX : 445.77 (+0.63%)
BBH : 187.49 (+0.77%)
Vertex to Participate in Upcoming May Investor Conferences

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and...

VRTX : 445.77 (+0.63%)
5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call

5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call

VRTX : 445.77 (+0.63%)
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

-The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany-

VRTX : 445.77 (+0.63%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which...

See More

Key Turning Points

3rd Resistance Point 458.48
2nd Resistance Point 453.99
1st Resistance Point 449.88
Last Price 445.77
1st Support Level 441.28
2nd Support Level 436.79
3rd Support Level 432.68

See More

52-Week High 507.92
Fibonacci 61.8% 452.37
Last Price 445.77
Fibonacci 50% 435.21
Fibonacci 38.2% 418.05
52-Week Low 362.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.